Literature DB >> 8583393

Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds.

G P Sgaragli1, M Valoti, M Palmi, M Frosini, M G Giovannini, L Bianchi, L Della Corte.   

Abstract

A single oral dose of 90 mg kg-1 chlorimipramine or chlorpromazine, corresponding to 54.5 or 55.9 mumol, respectively, was given to male Sprague-Dawley rats and concentrations of parent drugs and their N-desmethyl metabolites measured by gas chromatography in plasma and major organs (brain, liver, lung, kidney, heart, spleen and peritoneal fat). In the case of chlorimipramine, N-desmethyl metabolite levels were consistently higher than those of the parent drug for the entire observation period of 24 h in all tissues except fat, while lower N-desmethyl metabolite/parent compound ratios were observed for chlorpromazine. N-Desmethyl metabolite kinetics of chlorimipramine appeared to be elimination-rate limited, while those of chlorpromazine were formation-rate limited. In all analysed organs, the maximu detectable drug+metabolite concentrations accounted for only 2.3 and 4.6% of the initial dose of chlorimipramine and chlorpromazine. Chlorpromazine treatment gave rise to an area under the total amount-time curve (AUC0-24) for parent drug+metabolites, 3.9-fold that for chlorimipraine. Closer scrutiny discloses a conversion ratio of parent compound to N-desmethyl metabolite of 1.1 for chlorpromazine and of 2.2 for chlorimipramine, indicating the greater efficiency of chlorimipramine metabolism in all compartments. The expected high conversion index found in the liver (2.3) reaches its maximum of 5.4 in the lung. Fractional data analysis of chlorimipramine and chlorpromazine distribution patterns revealed greater organ transfer for the N-desmethyl metabolites than for the more stably-located parent compounds. The N-desmethyl metabolites of chlorimipramine apparently moved from liver to lung, kidney and spleen, whereas N-desmethylchlopromazine moved preferentially to the brain and lung tissue. This single dose study of chlorimipramine and chlorpromazine kinetics, highlights the two distinct dispositional processes at work in the rat in all likelihood, attributable to different absorption patterns, to a slower metabolism and, thus, to the longer persistence of chlorpromazine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8583393     DOI: 10.1111/j.2042-7158.1995.tb06741.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

2.  Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; Hong-Jie Yuan; C Lindsay Devane
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-10       Impact factor: 4.080

3.  The bio-distribution of the antidepressant clomipramine is modulated by chronic stress in mice: effects on behavior.

Authors:  Georgia Balsevich; Christian Namendorf; Tamara Gerlach; Manfred Uhr; Mathias V Schmidt
Journal:  Front Behav Neurosci       Date:  2015-01-06       Impact factor: 3.558

4.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

5.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

6.  Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.

Authors:  Marion Plaze; David Attali; Matthieu Prot; Anne-Cécile Petit; Michael Blatzer; Fabien Vinckier; Laurine Levillayer; Jeanne Chiaravalli; Florent Perin-Dureau; Arnaud Cachia; Gérard Friedlander; Fabrice Chrétien; Etienne Simon-Loriere; Raphaël Gaillard
Journal:  Int J Antimicrob Agents       Date:  2020-12-30       Impact factor: 5.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.